摘要
目的观察洛铂联合替吉奥治疗晚期食管癌的疗效及安全性。方法 32例晚期食管癌患者均采用洛铂联合替吉奥化疗。结果全组32例晚期食管癌患者中,CR 1例,PR 9例,SD 10例,PD 12例,有效率为31.25%,疾病控制率为62.50%。主要毒副反应为骨髓抑制,其中Ⅲ、Ⅳ度白细胞减少发生率43.75%(14/32),Ⅲ、Ⅳ度血小板减少发生率21.88%(7/32),Ⅲ、Ⅳ度贫血发生率9.38%(3/32)。结论洛铂联合替吉奥晚期食管癌的疗效较好,毒副反应可耐受。
Objective To evaluate the efficacy and safety of lobaplatin plus S-1 for patients with advanced e- sophageal carcinoma. Methods Thirty-two patients with advanced esophageal carcinoma received lobaplatin plus S- 1 chemotherapy. Results Of the 32 patients, CR was observed in the 1 patient,PR in the 9 patients, SD in the 10 patients, PD in the 12 patients, the overall response rate was 31.25%, and the disease control rate was 62.50%. The main toxicities were marrow depression, the incidence of grade Ⅲ and Ⅳ neutropenia was 43.75%, that of grade Ⅲ and Ⅳ thrombocytopenia was 21.88% ,that of grade Ⅲ and Ⅳanemia was 9.38%. Conclusion Loba- platin plus S-1 chemotherapy is effect and safe for patients with advanced esophageal carcinoma.
出处
《肿瘤基础与临床》
2015年第4期295-297,共3页
journal of basic and clinical oncology
关键词
洛铂
替吉奥
晚期食管癌
lobaplatin
S-I
advanced esophageal carcinoma
